Citigroup Maintains Buy on Spyre Therapeutics, Raises Price Target to $97

Benzinga Newsdesk www.benzinga.com Positive 83.6%

Neg 0% Neu 0% Pos 83.6%

Citigroup analyst Samantha Semenkow maintains Spyre Therapeutics (NASDAQ:SYRE) with a Buy and raises the price target from $64 to $97.